What are the limitations of the msmart 3 0?

While the msmart 3 0 is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the msmart 3 0 to ensure safe bedside use and optimal diagnostic accuracy.

How does the msmart 3 0 compare to other Hematology scores?

The msmart 3 0 is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the msmart 3 0 free to use?

Yes. OpiCalc provides the msmart 3 0 completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

OpiCalc

935 Clinical Tools

OpiCalc

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

mSMART 3.0 (Myeloma)

mSMART 3.0: Guidelines for risk-adapted therapy. Presence of multiple High-Risk features (Double/Triple Hit) indicates aggressive biological drive.

Risk Assessment (mSMART 3.0)

Standard Risk

0 Adverse Factors Identified

Standard biological risk profile. VRd induction followed by standard maintenance typically indicated.

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Prognostic stratification of newly diagnosed Multiple Myeloma to guide therapy selection.

Identifying high-risk patients who may benefit from proteasome inhibitor (PI) maintenance or quadruplet induction.

Differentiating double-hit and triple-hit myeloma phenotypes.

Patient Population

Adult patients with newly diagnosed, symptomatic Multiple Myeloma.

Section 2

Formula & Logic

High-Risk Features

High-risk translocation: t(4;14), t(14;16), or t(14;20)

Deletion 17p (del 17p) or TP53 mutation

Gain or Amplification of 1q (1q21)

High-risk Gene Expression Profile (GEP)

Clinical High-Risk

Plasma Cell Leukemia (primary)

High LDH (> 2x ULN)

Double/Triple Hit Myeloma

The presence of two or more high-risk genetic features (Double-Hit) or three or more (Triple-Hit) identifies a population with extremely poor prognosis even with modern therapy.

Section 3

Pearls/Pitfalls

The 1q Gain Controversy

mSMART 3.0 was among the first major guidelines to formally integrate 1q gain as a high-risk feature. While common (30-40% of cases), its impact is most significant when associated with other risk factors or when present in multiple copies (amplification).

Section 4

Evidence Appraisal

Primary Score

Mayo Stratification for Myeloma and Risk-Adapted Therapy (mSMART) Tiered Risk Stratification.

Rajkumar SV et al. • Mayo Clinic Proceedings. 2013-2022 (Updates);Current website version 3.0.

View Source

Section 5

Literature

Philosophy

Developed by the Mayo Clinic Myeloma Group. Its core philosophy is that high-risk patients should receive more intensive, continuous therapy (PI + IMiD) to overcome biological resistance.

Last Comprehensive Review: 2026

Related Hematology Tools

Deauville Score Interpreter

CLL-IPI

Binet / Rai Staging

iwCLL Response Criteria

Revised Response Criteria

PCNSL MSKCC Score

ISS

R-ISS

IMWG Response Criteria

MRD Assessment Threshold Interpreter

Have feedback about this calculator?Let us know.